Format

Send to

Choose Destination
Trends Immunol. 2001 Feb;22(2):102-7.

Viral vectors for dendritic cell-based immunotherapy.

Author information

1
Department Dermatology, University of Erlangen-N├╝rnberg, Hartmannstrasse 14, D-91052, Erlangen, Germany.

Abstract

Transduction of dendritic cells (DCs) by viral vectors genetically engineered to express tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction allows the control of DC quality, antigen quantity and site of DC reinjection. This review evaluates the viral vectors currently being developed for use in DC-based immunotherapy.

PMID:
11286712
DOI:
10.1016/s1471-4906(00)01813-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center